Aldeyra's Third FDA Rejection Crashes Stock 68%; CytomX Masked ADC Surges 60%

Aldeyra Therapeutics gets its third complete response letter for reproxalap — shares crater roughly 68 percent this morning.

Meanwhile, CytomX jumps more than 60 percent on masked ADC data in colorectal cancer, Bicycle Therapeutics cuts 30 percent of its workforce, and Pfizer puts real numbers behind its Ibrance successor. Busy Tuesday.

Welcome to The Pharma Closeout for Tuesday, March 17, 2026. I'm Alex Mercer.

And I'm Maya Patel. Let's get into it.

We flagged this PDUFA yesterday. The action date for Aldeyra's reproxalap was March 16, and the FDA delivered a complete response letter — the third CRL for this program. Aldeyra stock is down roughly 68 percent as of this morning, per Benzinga and StocksToTrade.

Three CRLs for the same NDA. The FDA extended the timeline back in December after requesting the clinical study report from Aldeyra's dry eye field trial. The agency got exactly the data it asked for and still said no. That's not a paperwork issue — that's an evidentiary gap the company hasn't been able to close.

And this is essentially a single-asset company. Reproxalap — the RASP inhibitor eye drop for dry eye disease — that is the pipeline. A 68 percent crash reflects the market pricing this program as done.

For listeners less familiar with the mechanism — RASP inhibitors target reactive aldehyde species, which are inflammatory mediators in the ocular surface. The idea is upstream intervention. But the dry eye space has been notoriously hard from a regulatory standpoint, and most programs that stumble, stumble once. Getting a third CRL after providing data the FDA specifically requested suggests the efficacy signal the agency needs simply isn't emerging from these datasets.

So what does Aldeyra do now? Can they run another trial at this valuation?

Funding a new registrational study would require massive dilution — and that assumes anyone participates at this market cap. But here's the broader question for the field: is this the dataset that closes the book on the RASP mechanism in ophthalmology, or just on Aldeyra's execution of it? Because there's a meaningful difference. If the biology is sound and the trial design was wrong, someone else picks it up. If the signal isn't there, the whole thesis dies. For competitors and investors watching this space, parsing that distinction is everything.

The other side of today's scoreboard — CytomX Therapeutics. Shares up more than 60 percent after Phase 1 expansion data for varsetatug masetecan, their EpCAM-targeting Probody ADC, in late-line colorectal cancer. Per BioPharma Dive, results surpassed Wall Street benchmarks. CytomX's CEO said the data reinforce Varseta-M's potential to meaningfully improve standard of care in that setting.

The masking technology is what separates this from a crowded ADC field. EpCAM is ubiquitously expressed on epithelial tissue — you can't just carpet-bomb it systemically without destroying healthy gut lining along the way. Conditional activation at the tumor drives the therapeutic window. And Phase 1 expansion data already prompting registrational discussions with the FDA — that pace signals the safety-efficacy balance is genuinely differentiated.

Staying in oncology — Pfizer put hard numbers behind atirmociclib, the selective CDK4 inhibitor being positioned as the next generation after Ibrance. Phase 2 data from the FOURLIGHT-1 study: atirmociclib plus fulvestrant reduced the risk of disease progression or death by 40 percent. That's in HR-positive, HER2-negative advanced breast cancer patients who had already progressed on a prior CDK4/6 inhibitor. Per Reuters.

The post-progression population is critical context. These patients already failed on a CDK4/6 inhibitor — palbociclib, ribociclib, abemaciclib — and atirmociclib still showed meaningful PFS benefit. Selective CDK4 inhibition may preserve activity against cells that developed resistance through CDK6-dependent escape. That's a pharmacologically distinct proposition, not just an incremental line extension. One analyst described atirmociclib as critical to Pfizer's oncology strategy, and the 40 percent hazard reduction in that setting supports the framing.

Two more items, quickly. Bicycle Therapeutics announced a 30 percent workforce reduction and is pivoting away from its Padcev-competitive bladder cancer program. Per BioPharma Dive and Endpoints News, the company now expects a longer regulatory path than anticipated. And Rhythm Pharmaceuticals disclosed that Imcivree missed its primary endpoints in the Phase 3 EMANATE trial across four rare genetically driven obesities. Rhythm still has a PDUFA approaching for Imcivree in a broader indication, so the read-through isn't straightforward — but a Phase 3 miss narrows the narrative.

The Bicycle story deserves a beat. When a well-capitalized biotech with a genuinely differentiated modality — bicycle toxin conjugates aren't just another ADC — decides the path to approval can't compete with Padcev's entrenchment, that's a competitive signal about how dominant Seagen and Pfizer's franchise has become in urothelial carcinoma. It's less about Bicycle's science failing and more about the regulatory and commercial bar being set impossibly high by the incumbent.

On the regulatory front — a federal court blocked HHS Secretary Kennedy's efforts to overhaul U.S. vaccine policy. The ruling came from a lawsuit filed by several major medical organizations. The court found that HHS ignored established protocols when it moved to alter the childhood immunization schedule and restructure a key CDC advisory panel.

For Pfizer, Merck, Sanofi, GSK, Moderna — this preserves the status quo. But it's a court injunction, not a final resolution. The policy intent at HHS hasn't changed. The court said the process was wrong, not the goal.

Which means the litigation continues, and uncertainty lingers. Separately — STAT News reports the White House is intensifying pressure on Congress to codify most-favored-nation drug pricing, despite a cool reception from lawmakers. And here's what caught my attention: Endpoints is reporting that drugmakers are already exploring licensing deal restructuring to mitigate MFN exposure.

That's the detail that matters most. When commercial teams start preemptively restructuring deal terms around a policy that hasn't even been legislated, you know the scenario modeling has moved from hypothetical to operational. The revenue impact is being priced into new agreements right now.

And for anyone building five-year revenue forecasts, the implication extends beyond MFN itself. Even if this specific legislation stalls, the pricing pressure it represents is already embedded in how deals get structured. The contracts being signed this quarter will reflect a world where international reference pricing is a live risk — whether or not the bill ever passes.

Looking ahead — GSK's linerixibat has a PDUFA date of March 24, one week from today. That's a cholestatic pruritus decision worth tracking closely. And the 20th International Conference on Alzheimer's and Parkinson's Diseases runs through March 21 this week, with additional biomarker and clinical data expected across several neuroscience programs.

AD/PD tends to produce incremental updates rather than pivotal readouts. But in neuro, where the clinical landscape is shifting faster than it has in a decade, incremental data can reshape competitive positioning quickly — especially for programs jockeying for differentiation ahead of late-stage decisions.

And that is your Pharma Closeout for Tuesday, March 17th — Aldeyra's third rejection and a 68 percent freefall, CytomX validating masked ADCs in colorectal cancer, Pfizer's atirmociclib delivering a 40 percent PFS reduction post-CDK4/6 failure, and Bicycle retreating from bladder cancer against an entrenched Padcev. A day that shows how fast this industry can build you up or knock you down. If you want to stay across this space, follow us on Spotify and drop a rating — we're back tomorrow.

Have a great evening. See you tomorrow. ### Episode Metadata **Title:** Aldeyra's Third FDA Rejection Crashes Stock 68%; CytomX Masked ADC Surges 60%; Pfizer Ibrance Successor Data | Mar 17, 2026 **Description:** Aldeyra Therapeutics crashes ~68% after the FDA rejects reproxalap for the third time. CytomX jumps 60%+ on masked ADC data in colorectal cancer. Pfizer's atirmociclib shows 40% PFS reduction in post-CDK4/6 breast cancer. Plus: court blocks RFK Jr. vaccine overhaul, MFN pricing reshapes deal structures, and Bicycle retreats from Padcev. **Tags:** Aldeyra Therapeutics, reproxalap, CRL, dry eye disease, CytomX, varsetatug masetecan, masked ADC, colorectal cancer, Pfizer, atirmociclib, Ibrance, CDK4, breast cancer, Bicycle Therapeutics, Padcev, Rhythm Pharmaceuticals, Imcivree, RFK Jr, vaccine policy, most favored nation, MFN, drug pricing, GSK, linerixibat, pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals #